Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 12

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 12
---
clinical biotechnology company developing lipid-based therapies to address some of the most pressing challenges in medicine. We focus
on creating smarter, more targeted treatments that improve how medicines work in the body, with the goal of increasing effectiveness
while reducing side effects. We are developing lipid-based formulations for a variety of potential uses, including areas with high unmet-needs
such as antimicrobial resistance and solid tumors. Our planned clinical trials aim to expand the therapeutic horizons of hard-to-treat
diseases by amplifying, improving, and unleashing the potential of encapsulated therapeutics to enhance delivery and achieve a controlled
release. This includes antimicrobial resistance and solid tumors being as they are areas with high unmet need.

We plan to use tiny, specially designed fat-based
particles called liposomes to carry powerful medicines directly to where they’re needed in the body. This method is one of the
most advanced ways to deliver medicine and allows the drugs to stay in the bloodstream longer, reach their target more precisely, and
release their effects in a controlled way. We plan to leverage these features to direct our proposed treatments toward diseased tissues,
tumors and infected areas, and reduce the impact on healthy cells as much as possible. We address unmet medical needs in antibiotic resistant
microbial, oncology, and immunology through the development of lipid-based therapeutics. By combining established pharmacology with advanced
lipid delivery systems, our development efforts aim to improve drug efficacy, optimize safety profiles, and enable targeted delivery,
which parameters will need to be established in future clinical trials.

Our work is inspired by Prof. Barenholz, a world
renown expert in this field and one of the original innovators behind liposomal drug delivery. His decades of research have shaped some
of today’s most important cancer treatments. At Revium Rx, we’re taking this legacy further, using this technological approach
to design and develop next-generation therapies to help meet some of the most urgent medical needs.

Our pipeline, which
is comprised of drug candidates in various stages of development, includes advanced delivery systems for a variety of indications, including
a liposomal antibiotic targeted at fighting drug-resistant infections and a liposomal therapy designed to boost the impact of cancer
treatments.

Our product candidates
are in early stages of development and have not yet been approved for clinical trials in the United States or elsewhere.

Corporate History and Recent Developments

Revium Rx was incorporated on January 24, 1997
as a Delaware corporation